Literature DB >> 2171745

Identification of somatostatin receptors in human small cell lung carcinoma.

U Sagman1, J B Mullen, K Kovacs, R Kerbel, R Ginsberg, J C Reubi.   

Abstract

Biopsy specimens obtained from eight patients with lung cancer were tested for content of somatostatin receptors by autoradiography. Somatostatin receptors were detected in two of three patients with small cell lung cancer (SCLC) but in none of five patients with non-small cell lung cancer (NSCLC) including adenocarcinoma (two), squamous cell carcinoma (two), and bronchoalveolar carcinoma (one). In those with SCLC, specific somatostatin receptor binding was evidenced only in tumor foci and not in surrounding stroma or normal lung parenchyma. Further tissue characterization by immunoperoxidase staining with the pancytokeratin monoclonal antibody, mAB-lu-5, revealed labeling to all of the NSCLC but to none of the SCLC specimen. Selective immunoreactivity was detected in both the SCLC and the NSCLC specimen to chromogranin and neuron-specific enolase (NSE) whereas none of the specimen had detectable immunostaining to somatostatin, bombesin, serotonin, adrenocorticotropic hormone, neurofilament, calcitonin, and synaptophysin. The identification of somatostatin receptors in primary human lung cancer may have a bearing on the biology of this disease and perhaps on the clinical application of somatostatin analogues in patients with SCLC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171745     DOI: 10.1002/1097-0142(19901115)66:10<2129::aid-cncr2820661015>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

Review 2.  The diagnostic utility of somatostatin receptor scintigraphy in oncology.

Authors:  R Valkema; J Steens; F J Cleton; E K Pauwels
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.

Authors:  C H van Eijck; S W Lamberts; L C Lemaire; H Jeekel; F T Bosman; J C Reubi; H A Bruining; E P Krenning
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

4.  Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma.

Authors:  C M Kirsch; J von Pawel; I Grau; K Tatsch
Journal:  Eur J Nucl Med       Date:  1994-12

5.  Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication.

Authors:  Anna Płachcińska; Renata Mikołajczak; Helmut R Maecke; Ewa Młodkowska; Jolanta Kunert-Radek; Andrzej Michalski; Katarzyna Rzeszutek; Józef Kozak; Jacek Kuśmierek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-05       Impact factor: 9.236

6.  ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.

Authors:  Volker H Schartinger; József Dudás; Clemens Decristoforo; Christoph Url; Johannes Schnabl; Georg Göbel; Irene J Virgolini; Herbert Riechelmann; Michael Rasse; Dietmar Waitz; Daniel Putzer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-18       Impact factor: 9.236

7.  Localization of small-cell lung cancer xenografts with iodine-125-, indium-111-, and rhenium-188-somatostatin analogs.

Authors:  M Hosono; M N Hosono; T Haberberger; P O Zamora; S Guhlke; H Bender; F F Knapp; H J Biersack
Journal:  Jpn J Cancer Res       Date:  1996-09

Review 8.  Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging.

Authors:  Rami Alrezk; Andres Suarez; Isabel Tena; Karel Pacak
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-27       Impact factor: 5.555

9.  Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.

Authors:  K J O'Byrne; J T Ennis; P J Freyne; L J Clancy; J S Prichard; D N Carney
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.